European Psychiatry - Volume 33 - March 2016

299 / 812

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S116–S348 S295
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
Acknowledgements L. Galindo is a Rio-Hortega-fellowship-(ISC-
III; CM14/00111).
EW515
Differential peripherical biomarkers
in severe mental illness
L. Garcia-alvarez ∗ P. Garcia-portilla
L. Gonzalez-blanco e La Fuente Tomas glesias
P. Saiz Martinez obes
1 Centro de Investigación Biomédica en Red de Salud Mental,
CIBERSAM G05, Oviedo, Spain
2 Universidad de Oviedo, Área de Psiquiatría, Oviedo, Spain
3 Servicio de Salud del Principado de Asturias, SESPA, Oviedo, Spain
4 Servicio de Salud del Principado de Asturias, SESPA, Langreo, Spain
∗ Corresponding author.
Introduction Patients with schizophrenia and bipolar disorder
have higher rates of medical comorbidities and mortality than gen-
eral population
Aims To find severe mental illness biomarkers. Here, we present
the peripherical biological parameters of patients with schizophre-
nia (SCH), bipolar disorder (BD) and healthy subjects (HS).
Methods Cross-sectional, naturalistic study. Inclusion criteria:
DSM-IV diagnosis of schizophrenia or bipolar disorder; age > 17
years; and written informed consent given.
Results One hundred and twenty-three SCH, 102 BD and 80
HS. Laboratory tests: red cells, haemoglobin, leukocyte, platelets,
glucose, urea, creatinine, uric acid, cholesterol, HDL-cholesterol,
LDL-cholesterol, triglycerides, GPT, AP, CA, P, FE, insulin, HbA1c
and TSH. Age and gender were used as covariates. There
were differences in: HDL-cholesterol (P< 0.0001), triglycerides
(P < 0.0001), insulin (P < 0.0001), AP (P = 0.006) and TSH (P = 0.013).
The differences were between SCH and HS (HDL-cholesterol,
triglycerides, insulin, AP and TSH), and, between BD and HS (HDL-
cholesterol, triglycerides, insulin and TSH), but not between SCH
and BD.
Conclusion There are differences in peripherical biological
parameters between patients with SCH or BD and HS. Biological
biomarkersmay play a role in severemental disorders pathogenesis
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
References
[1] Physical illness and schizophrenia: a review of the literature.
Acta Psychiatr Scand 2007;116(5):317–33.
[2] Bipolar disorder and comorbidity: increased prevalence and
increased relevance of comorbidity for hospital-based mortal-
ity during a 12.5-year observation period in general hospital
admissions. J Affect Disord 2014;169(170–8).
EW516
Paliperidone palmitate log-acting
injection in patients with psychotic
active clinic: start, change or increase
of dose
A.L. Gonzalez Galdamez ∗, M.D. Piqueras Acevedo ,
M.R. Raposo Hernández , I. Martínez Pérez , P. Manzur Rojas ,
A. Gil Sánchez , A. Belmar Simo , A. Busaileh Salas ,
F. González Jiménez , R. Sánchez Marín , S. Gómez Bravo ,
C.J. García Bri˜nol , A. Rodriguez Hernandez
Santa Lucia Hospital, Psychiatry, Cartagena-Murcia, Spain
∗ Corresponding author.
The aim is to describe the experience of treatment with Paliperi-
done Palmitate long acting injection (PP) in patients with psychotic
active clinic, whether diagnoses with schizophrenia or in patients
with the first episode psychosis, as well as to reflect the improve-
ment in the control of the symptoms that the patients can improve
increasing the dose.
Methods We have done a descriptive study of 34 patients hospi-
talized in psychiatry between January and July 2015 for psychotic
active clinic who started treatment with PP or the previous dose
was increased.
Results 91.2% of patients admitted for acute exacerbation of their
usual pathology and 8.8% for a first episode psychosis. In the CGI
scale, all the patients admitted scored as severe or markedly ill;
going mostly mildly ill at discharge. For 55.9% of patients, the treat-
ment was changed to PP, 29.4% of the dose was increased PP and
14.7% antipsychotic treatment was startedwith PP. Among patients
change treatment, the main reason was non-adherence (47.4%).
70.6% of our patients were dischargedwith PP as only antipsychotic
and 29.4% which was discharged with another antipsychotic, the
most frequent association was of PP with Quetiapine (80%).
Conclusions PP is a highly effective medicament in the treatment
of the schizophrenia that improves the adherence to the treatment,
so in our experience and we consider it a medicament to be consid-
ered in the early stages of the disease. According to our experience
and there are patients who can benefit frombetter control of symp-
toms adjusting the dose individually.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW517
Inflammatory and metabolic
biomarkers of psychopathological
dimensions of schizophrenia
L. Gonzalez-Blanco ∗ . García-Portilla
L. Garcia-Alvarez glesias aiz Coto
J. Bobes
1 Servicio de Salud del Principado de Asturias, Psiquiatría, Oviedo,
Spain
2 Universidad de Oviedo, Área de Psiquiatría, Oviedo, Spain
3 Centro de Investigación Biomédica en Red de Salud Mental,
CIBERSAM, Oviedo, Spain
4 Servicio de Salud del Principado de Asturias, Psiquiatría, Langreo,
Spain
5 Universidad de Oviedo, Morfología y Biología Celular, Oviedo, Spain
∗ Corresponding author.
Introduction The concept of schizophrenia as a systemic disease
includes, not only psychosis, but an increase in somatic comor-
bidity and cardiovascular risk Furthermore, it is known the
implication of inflammation in the pathogenesis of schizophrenia
Objectives To determinate potential inflammatory/metabolic
biomarkers of schizophrenia’s dimensions.
Methods Sample: 36 outpatientswith schizophrenia for less than
11 years, under stable maintenance treatment (mean age [32.25],
males [63.9%]) and their 36 matched controls (age [32.53± 6.63];
males [72.2%]).
Evaluation PANSS, Clinical Assessment Interview for Negative
Symptoms(CAINS), Calgary Scale(CDS), CGI, Personal and Social
Performance Scale(PSP). Biomarkers: C-reactive protein (CRP),
homocysteine, glucose, insulin, HOMA-IR (insulin resistance),
cholesterol, HDL, LDL, triglycerides.
Results Biomarkers differences between groups are shown in
hows the correlations found after controlling for
Body Mass Index [patients(28.61 ± 5.69);controls(24.64± 3.80);
p = 0.001] and Smoking [patients(52.8%-yes);controls(5.6%-
yes);p = 0.000].